Table 1 Demographics of Eyes with Uveitic Cystoid Macular Edema, Comparing Eyes with and Without Subretinal Fluid at Presentation, N = 93
Characteristic | No Subretinal Fluidn = 47 | Subretinal Fluidn = 46 | p-value |
|---|---|---|---|
Gender | 0.64 | ||
Male | 22 (46.8%) | 19 (41.3%) | |
Female | 25 (53.2%) | 27 (58.7%) | |
Age, Mean (SD), Years | 45.2 (20.1) | 57.0 (17.8) | 0.02 |
Race | 0.007 | ||
White | 41 (87.2%) | 28 (60.9%) | |
Black | 2 (4.3%) | 16 (34.8%) | |
Hispanic* | 2 (4.3%) | 2 (4.4%) | |
Asian* | 2 (4.3%) | 0 (0%) | |
Location, No. (%) of patients | 0.84 | ||
Anterior | 4 (8.5%) | 5 (10.9%) | |
Anterior and Intermediate | 3 (6.4%) | 5 (10.9%) | |
Intermediate | 25 (53.2%) | 20 (43.5%) | |
Panuveitis** | 13 (27.7%) | 16 (34.8%) | |
Posterior** | 2 (4.3%) | 0 (0%) | |
Origin, No. (%) of patients | 0.05 | ||
Associated Systemic Disease | 3 (6.4%) | 2 (4.4%) | |
HLA-B27 | 2 (4.3%) | 3 (6.5%) | |
Multiple Sclerosis | 0 (0%) | 2 (4.4%) | |
Sarcoidosis | 0 (0%) | 6 (13.0%) | |
Undifferentiated*** | 42 (89.4%) | 33 (71.7%) | |
Treatment prior to presentation**** | |||
Local steroids | 14 (29.8%) | 12 (26.1%) | 0.71 |
Systemic steroids | 5 (10.6%) | 3 (6.5%) | 0.57 |
Immunomodulatory Therapy | 12 (25.5%) | 10 (21.7%) | 0.69 |
Treatment at presentation**** | |||
Local steroids | 34 (72.3%) | 32 (69.6%) | 0.79 |
Systemic steroids | 1 (2.1%) | 2 (4.4%) | 0.55 |
Immunomodulatory Therapy | 4 (8.5%) | 0 (0%) | 0.12***** |